Dr Brandon Shank: Reimbursement Challenges With Biosimilars

Brandon Shank, PharmD, MPH, BCOP, Clinical Pharmacy Specialist, discusses the potential for reimbursement challenges with biosimilars.


Will there be reimbursement challenges with biosimilar products?

I think it’s too soon right now to say, exactly. It is a very complicated payer system, and there are a lot of incentives—for the hospitals, the patients, and the insurance companies. I hope that patients will see some of the cost savings, as well as insurances, and hospitals will be incentivized, hopefully, to add these agents on to their formulary and pass on the cost savings to the entire health care system both at a payer base and a patient-care level.